Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of isoquinoline alkaloid to prevention or treatment of diabetes

A technology for isoquinoline alkaloids and diabetes, which is applied in the field of natural medicines and can solve problems such as no preventive or therapeutic effects of phellodendri

Inactive Publication Date: 2016-11-23
CHINA PHARM UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] There is no report about the preventive or therapeutic effect of Phellodendronine on non-alcoholic fatty liver

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of isoquinoline alkaloid to prevention or treatment of diabetes
  • Application of isoquinoline alkaloid to prevention or treatment of diabetes
  • Application of isoquinoline alkaloid to prevention or treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0070] In order to study the effect of cortex base on the blood sugar of type I diabetes, this experiment adopts the classic type I diabetes model, and uses C57BL mice to be randomly divided into 3 groups, normal control group (10 rats), STZ group (20 rats). In the STZ group, STZ (50mg / Kg) was injected intraperitoneally continuously for 5 days, and the fasting blood glucose was measured two weeks later. If the blood glucose was greater than or equal to 13.8mmol / L, the modeling was successful. Then STZ group is randomly divided into STZ group and Phellodendron treatment group, every group of 10, Phellodendron treatment group adopts oral gavage (15mg / kg) after 10 weeks, measures fasting blood glucose result after fasting 4h as follows: figure 1 showed a statistically significant difference.

[0071] General condition of the animal:

[0072] Histopathological examination of pancreatic islets: paraffin section, HE staining, observation of pathological changes

[0073] Table 1. T...

Embodiment 2

[0082] In order to study the influence of Phellodendronine on type II diabetes, this experiment adopts the classic Type II diabetes model, and uses C57BL mice to be randomly divided into 3 groups, normal control group (10 mice), model group (10 mice), and Phellodendronine treatment group. (10), wherein the model group and the cortex base treatment group adopt high-fat diet (basic feed adds 20% lard) to make models for 8 weeks, and the cortex base treatment group adopts oral gavage (50mg / kg) mode while high-fat diet After administration, fasting overnight assay, fasting blood glucose, glucose tolerance and insulin tolerance were measured after administration. The experimental data were subjected to analysis of variance, and the results were expressed as x±s. The results showed that Phellodendronine treatment effect was obvious, with significant statistical difference.

[0083] Experimental results:

[0084] Table 3. Effects of Phellodendronine on Fasting Blood Glucose in Type...

Embodiment 3

[0119] Therapeutic effect of cortex base on hyperlipidemia and non-alcoholic fatty liver,

[0120] 1. Experimental animals and methods:

[0121] C57BL mice, SPF grade, male, body weight (20 ± 2) g, were randomly divided into two groups, the first group of 12 was the normal group, and was given normal feed, and the remaining mice (44) were divided into the second group, Give high-fat feed (basic feed with 20% lard, 1.25% cholesterol, 0.5% sodium cholate) to eat and drink freely. After 8 weeks of continuous feeding, 4 mice from the normal control group and the fatty liver model group were sacrificed respectively, and the serum and liver biochemical indicators of the two groups of mice were compared, as well as the liver tissue pathological sections, to determine whether the non-alcoholic fatty liver model mice were Created successfully.

[0122] 32 successful modeling mice were randomly divided into 4 groups, which were respectively normal control group (8 mice), model group (...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to isoquinoline alkaloid for preparation of composition for prevention or treatment of diabetes.

Description

technical field [0001] The invention relates to the field of natural medicines, in particular to the use of isoquinoline alkaloids for preventing or treating diabetes, in particular to the use of phellodine for preventing or treating diabetes. Background technique [0002] Diabetes mellitus is a metabolic disease characterized by hyperglycemia caused by defects in insulin secretion and / or its biological function. Metabolic diseases seriously endanger human health, and active prevention and treatment of diabetes has become a major social public health problem. [0003] The pathogenesis of type I diabetes is mainly due to the absolute lack of insulin secretion, and type II diabetes is a pathological process from insulin resistance mainly accompanied by relative insulin deficiency to insulin secretion mainly accompanied by insulin resistance. Type II diabetes is currently recognized as a complex genetic disease caused by multiple genes separately or interacting under the influ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4375A61P3/10A61P5/50A61P3/06A61P1/16A23L1/30
Inventor 李萍徐晓军谢治深
Owner CHINA PHARM UNIV
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More